Old Articles: <Older 8751-8760 Newer> |
|
Pharmaceutical Executive December 1, 2013 Slota et al. |
Prescribed Behavior: Operating Under a Consent Decree For senior executives, meeting the requirements of a Consent Decree to the satisfaction of regulators is only half of the job. |
Pharmaceutical Executive December 1, 2013 |
Country Report: Canada Despite declining investments by big pharma in recent years, Canada has created a number of innovative ways to incentivize R&D and leverage its geographic reach in the North American Market. |
Pharmaceutical Executive December 1, 2013 |
FDA Pursues Delicate Balancing Act The Agency struggles to ensure access to needed medicines while minimizing potential risks, writes Jill Wechsler. |
Pharmaceutical Executive December 1, 2013 Ben Comer |
Brand vs. Generic: Physicians Weigh In Why do some doctors prescribe more generic drugs than others? |
Pharmaceutical Executive December 1, 2013 Vansgaard et al. |
Develop Drugs for People, Not Just Bodies A patient-centric approach to drug development delivers the benefits that actually create value |
Pharmaceutical Executive December 1, 2013 William Looney |
Big Stakes in Small Things New and emerging technologies are noteworthy not simply for the excellent science behind them but also for the way they expose those raw edges of the industry's business model. |
Chemistry World January 15, 2014 Dinsa Sachan |
Radical drug rule changes hit buffers in India A parliamentary panel in India has slammed a proposed bill seeking to radically alter the way drugs are regulated in India. The panel's report has essentially put reform of medicines in the country on ice, according to observers. |
Chemistry World January 9, 2014 Phillip Broadwith |
Novartis in the spotlight in mis-selling investigations Swiss firm Novartis is being sued by the attorney general's office in New York, US, for alleged mis-selling of its iron-chelating drug Exjade (deferasirox). |
AskMen.com Stephen Pym |
Pot Stocks On Fire, Lighting Up Market There are several marijuana-related stocks you can buy, across a diverse array of companies ranging from holding companies to services to technology. |
Chemistry World January 8, 2014 Phillip Broadwith |
Thermo Fisher to sell three analytical divisions to GE Healthcare GE will take over Thermo's cell culture supplies, gene modulation and magnetic beads businesses, which are expected to generate combined sales in the region of $250 million for 2013. |
<Older 8751-8760 Newer> Return to current articles. |